Leqvio FDA Approval
Confident in successful US launch
Effective and sustained LDL-C
reduction with twice a year
maintenance dose administered by HCP
✓ Broad label covering 16m
US ASCVD patients not at
LDL-C goal
✓ Go-to-market model designed to
overcome clinical barriers and address
access, adherence and affordability
Sales, reimbursement and
medical teams with deep experience
in the US cardiovascular market
Robust network of AICs to
provide acquisition and
administration flexibility
Value-based price
per dose
(USD 3,250)
✓ Comprehensive patient and HCP
support programs available at
launch to ensure timely access
✓ Product available from specialty
distributors in early January
LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease AIC Alternative Injection Center HCP Healthcare Professional 1. Across the 6-month dosing interval.
26 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
U NOVARTIS | Reimagining MedicineView entire presentation